Genialis, a medtech company, has raised $13 million in Series A funding to transform the way diseases are diagnosed and treatment decisions are made. Taiwania Capital and Debiopharm Innovation Fund co-led the round.
- Founded in 2015 and led by Rafael Rosengarten and Miha Stajdohar, Genialis is a computational precision medicines company currently based in Boston, US and Ljubljana, Slovenia. The company wants to propel drug development, diagnostics, and treatment planning through its platform, ResponderID.
- ResponderID is an AI/ML-enabled platform with a biology-first approach for clinical and translational research. It yields new biomarkers for drug development and discovery programs, as well as diagnostic tests. The resulting output can provide the most informed decision-making possible.
“Genialis has an impressively clear vision, compelling AI-drug discovery biomarker models, and robust underlying science supporting their platform. We look forward to working closely with the Genialis team to explore and pursue growth opportunities in this burgeoning space,”
Ita Lu, Managing Partner at Taiwania Capital Management, commented.
- The $13 million Series A round was co-led by Taiwania Capital, a Taiwan-based VC firm, and Debiopharm Innovation Fund, a Switzerland-based strategic investor. The previous investors First Star Ventures, Redalpine Venture Partners, and Pikas also participated, together with P5 Health Ventures and several angels.
- Genialis is currently growing its teams in both the US and Slovenia. The company is also investing in R&D collaborations with several leading cancer centers, hospital groups, and clinical academic labs.
- The fresh capital will help to expand its proprietary ResponderID platform and build out its collection of biomarker models to improve cancer treatment.
